Indivior Pharmaceuticals (INDV) EPS (Basic) (2024 - 2026)

Indivior Pharmaceuticals' EPS (Basic) history runs 3 years deep, the most recent figure standing at $0.71 for Q1 2026.

• In Q1 2026, EPS (Basic) rose 86.84% year-over-year to $0.71; the TTM figure through Mar 2026 stood at $2.01 (up 10150.0% YoY), while the FY2025 annual figure was $1.68, up 3260.0% from the prior year.
• EPS (Basic) was $0.71 for Q1 2026 at Indivior Pharmaceuticals, down from $0.81 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $0.81 in Q4 2025 to a low of -$0.72 in Q2 2024.
• Historically, EPS (Basic) has averaged $0.27 across 3 years, with a median of $0.34 in 2025.
• Biggest YoY gain for EPS (Basic) was 406.25% in 2025; the steepest drop was 15.56% in 2025.
• A 3-year view of EPS (Basic) shows it stood at $0.16 in 2024, then soared by 406.25% to $0.81 in 2025, then declined by 12.35% to $0.71 in 2026.
• The last three EPS (Basic) figures came in at $0.71 (Q1 2026), $0.81 (Q4 2025), and $0.34 (Q3 2025), per Business Quant data.